Putting Carevive SMART Data to Work

Carevive SMART Data is making waves in the pharmaceutical industry as it gets licensed to companies looking to enhance their value chain. This revolutionary dataset is being utilized for crucial use cases, particularly in clinical trials.

Pharmaceutical companies are now leveraging SMART Data to precisely target the right patient populations and determine essential patient experience measures for inclusion in their clinical trials. By integrating this definitive set of Patient-Reported Outcomes (PROs) into new study designs, trials gain a valuable dimension that bolsters the quality of trial data and strengthens regulatory submissions.

We’re excited to discuss Carevive SMART Data with you in-depth, showcasing how it can transform your clinical trials and regulatory strategies. Together, let’s pave the way for more effective and patient-centered therapies in the ever-evolving landscape of cancer care.

Recent Episodes

Healthcare leadership is being redefined in real time. With the rise of AI, mounting financial pressures, and workforce burnout, executives today are operating in an environment of continuous disruption and uncertainty. In fact, industry leaders now rank workforce shortages and digital transformation among their top concerns—forcing a new kind of leadership that blends decisiveness…

Healthcare systems are facing a workforce crisis that’s no longer temporary—it’s structural. Even before COVID-19, staffing shortages across nursing, technical, and administrative roles were already straining capacity; today, those gaps are wider, costlier, and directly impacting patient access. With labor shortages persisting and burnout rising, health systems are being forced to rethink not just…

Healthcare systems are entering 2026 under mounting pressure. A growing, aging population and rising disease burden are colliding with persistent workforce shortages—highlighted by projections that new cancer diagnoses in the U.S. will surpass two million this year alone. The stakes are no longer theoretical: delays in care, limited specialist access, and widening disparities are…